Thursday, March 23, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
D. Martin Carter Professor in Clinical Investigation
Head of Laboratory for Investigative Dermatology
Co-Director
Center for Clinical and Translational Science
The Rockefeller University Hospital
New York City, New York, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Non-US Physicians - maximum of 0.50 CPD
This activity is intended for a global audience of dermatologists, surgeons, primary care physicians, obstetricians & gynecologists, and emergency medicine physicians.
The goal of this activity is to highlight our current understanding of the immunopathogenesis of hidradenitis suppurativa (HS), its multifactorial etiology, and the role of the interleukin (IL)-17 pathway in the inflammatory process.
Upon completion of this activity, participants will:
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
D. Martin Carter Professor in Clinical Investigation
Head of Laboratory for Investigative Dermatology
Co-Director
Center for Clinical and Translational Science
The Rockefeller University Hospital
New York City, New York, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information about your
eligibility to claim
credit, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online
during the credit
eligibility period that is noted on the title page.
Follow these steps to claim a credit certificate for completing this activity:
We encourage you to complete an Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied
in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well
as the certificates by
accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CPD Released: 5/9/2022
Valid for credit through: 5/9/2023
processing....
Dieser Kommentar ist Teil einer umfangreicheren Fortbildungsmaßnahme. Kehren Sie für den Zugriff auf alle zugehörigen Fortbildungsinhalte nach Ihrer Teilnahme bitte zurück zu Immunopathogenesis of Hidradenitis Suppurativa .
| « Return to: Immunopathogenesis of Hidradenitis Suppurativa |
